[
    [
        {
            "time": "2018-03-15",
            "original_text": "What Does Clovis Oncology’s Valuation Trend Indicate?",
            "features": {
                "keywords": [
                    "Clovis Oncology",
                    "valuation trend"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What Does Clovis Oncology’s Valuation Trend Indicate?",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Better Buy: Eli Lilly and Company vs. GlaxoSmithKline",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "GlaxoSmithKline",
                    "better buy"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Better Buy: Eli Lilly and Company vs. GlaxoSmithKline",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "Tecentriq Could Boost Roche’s Revenue Growth in 2018 and Beyond",
            "features": {
                "keywords": [
                    "Tecentriq",
                    "Roche",
                    "revenue growth"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Tecentriq Could Boost Roche’s Revenue Growth in 2018 and Beyond",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]